Session 5: Collaboration Between Agencies and Future Expectations

Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Symposium
February 14, 2024 – 2:10 – 2:40 PM

Moderator: **Mandy Budwal-Jagait, MSc**
Head of GCP and *Lead Senior GCP Inspector* | MHRA

LaKisha Williams, MSN
Commander (CDR) | USPHS | DCCE | OSI | OC | CDER | FDA

Reza Salehzadeh-Asl, MSc
National Supervisor | ROEB | HC

Collaboration Between Our Agencies and Future Expectations

A Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Compliance Workshop
February 14, 2024

LaKisha Williams, MSN, CRNP, PMHNP-BC, GCP International Liaison, FDA
Reza Salehzadeh-Asl, MSc, National Supervisor, HC
Mandy Budwal-Jagait, MSc, Head of GCP and Lead Senior GCP Inspector, MHRA

U.S. FOOD & DRUG ADMINISTRATION

Medicines & Healthcare products Regulatory Agency

Health Canada Santé Canada

Overview

- Globalization of Clinical Trials and its challenges
- History of the FDA, MHRA & HC collaboration
- Benefits of the collaboration
- FDA, MHRA, & HC GCP collaboration process
- Future direction of our collaboration
- Update on current thinking and strategy
- Themes / workstreams
- Summary

U.S. FOOD & DRUG ADMINISTRATION

FDA-MHRA-HC Collaboration
The Past

A Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Compliance Workshop
February 14, 2024

LaKisha Williams, MSN, CRNP, PMHNP-BC

Commander, United States Public Health Service

Medicines & Healthcare products Regulatory Agency

Health Canada Santé Canada

Disclaimer

The views expressed in this presentation are those of the speaker and not necessarily those of the Food and Drug Administration.

Sharing of Non-Public Information (NPI)

- **21CFR 20.89**
  Describes conditions under which FDA may share some NPI with foreign counterparts
- Each agency has a current Memorandum of Understanding (MOU), Confidentiality Commitment (CC), or Cooperative Arrangement (CA), which allows us to share NPI.

Clinical Trials around the Globe

- Clinical trial is a global undertaking

- Most approved marketing applications for drugs and biologics contain foreign data

Global Coverage of FDA GCP Inspections

Conducted by FDA/CDER in 2023

Global Coverage of FDA GCP Inspections

Conducted by FDA/CDER in 2022



Challenges in GCP Inspections

- Increasing globalization of clinical trials
  - increase in numbers of non-U.S. based clinical investigators conducting research
- Finite inspection resources
  - Breadth of international inspections coupled with finite inspection resources result in inspection of a limited number of sites

Strategies to Address Issues Posed by Globalization & Finite Resources

FDA/MHRA/HC use diverse approaches to address GCP related challenges :

- Increase collaboration with foreign regulators and other stakeholders
- Develop internationally-harmonized standards & Guidance
- Educate foreign stakeholders about GCP compliance requirements

If regulators work collaboratively, implement information exchanges, then GCP inspection resources can be used more efficiently

History of FDA & MHRA GCP Collaboration

- OSI and MHRA began meeting regularly in 2016
- The key objectives of the collaboration include:
  - exchange GCP-related information including inspection outcomes
  - meet quarterly and as needed to discuss common applications
  - share GCP inspection planning information
  - conduct collaborative GCP inspections
  - keep each other informed of GCP-related legislation, regulatory guidance and related documents

Health Canada Santé Canada

HC-MHRA-FDA Collaboration- The Present

A Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Compliance Workshop

February 14, 2024

Reza Salehzadeh-Asl
National Supervisor
Clinical Trial Compliance Program
Regulatory Operations and Enforcement Branch
Health Canada

Welcoming Health Canada to the Collaboration

- Health Canada (HC) joined MHRA in 2018 and later in 2019 joined FDA- MHRA collaboration
  - FDA-MHRA-HC meets bi-monthly
- HC contributes and provides valuable input
  - Sharing information on inspection
  - Managing common risk files
  - Joint inspection and training

Benefits of Collaboration

- Gain a better understanding of each other's inspection procedures with the objective to harmonize and align processes (have common and predictable expectation from stakeholders)
  - Create greater consistency in regulatory approaches and reduces burden on stakeholders
- Discussing common risk issues and align regulatory actions
  - Clinal trials is a global activity so should be the associated compliance and enforcement
- Optimize inspection coverage to maximize the inspection outcome (avoid duplication and share inspection reports)
- Provide more efficient use of resources and expanded knowledge base

Collaborative Inspections

Observational	Joint
One regulator inspects while the other observes the inspection & highlight similarities & differences	Joint team shares in planning and conducting the inspection
• A confidence building training opportunity • About sharing practices	• Follow their own policies & procedures • Enter their own report into their own review system • Share mutual findings in order to be consistent in the outcome as much as possible

FDA-MHRA-HC Collaboration Process

- Foreign regulators may receive courtesy notifications of our plans to conduct inspections within their territory approximately 30 days prior to the inspection, in accordance with any signed confidentiality commitment/agreement/arrangement between our governments.
- We share inspection planning information and relevant compliance issues
- Educational learning
- Joint Workshops (2018, 2020, 2022, and current 2024)
- Harmonization

What Have We Been Up to Lately?



U.S. FOOD & DRUG ADMINISTRATION

MHRA-FDA-HC Collaboration- The Future

Mandy Budwal-Jagait
Head of GCP and Lead Senior GCP Inspector
Compliance Team 1, Standards & Compliance Group
HQA | MHRA

A Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Compliance Workshop
February 14, 2024

Medicines & Healthcare products Regulatory Agency

Health Canada Santé Canada

Collaboration Strategy

- Agree our strategic direction
- Strategy meetings held annually
- Review of current ways of working and new initiatives / workstreams

Future Direction

- Meeting frequency
- Information sharing
- Inspection plans
- Inspector training
- Stakeholder engagement and guidance
- Exploring patient and participant engagement activities
- Exploring use of technology on inspection

Information Sharing

INSPECTION PLANS

INSPECTION OPPORTUNITIES

INTELLIGENCE SHARING

CONTENT – APPLICATIONS, INSPECTION FINDINGS, INTELLIGENCE

Inspections

- Explore joint or observed inspection opportunities
- Training of inspectors
- Common applications
- Common compliance issues

Influencing Compliance

STAKEHOLDER ENGAGEMENT OPPORTUNITIES

KEY MESSAGES

COMMON COMPLIANCE ISSUES

AUDIENCE REACH

FORMAT OF MESSAGING

Summary

- Continue to strengthen our collaboration
- Explore opportunities for alignment and learning from each other.
- Influencing compliance though key messaging
- Training opportunities
- Information exchange
- Inspection opportunities and collaboration

Questions?

Mandy Budwal-Jagait
Head of GCP and Lead Senior GCP Inspector
Compliance Team 1, Standards and Compliance Group
HQA | MHRA

Copyright information